Thaum pib lub Peb Hlis, Lub Chaw Saib Xyuas Khoom Siv Kho Mob Hauv Tebchaws tau pom zoo Jaypirca® (pirtobrutinib) rau kev kho mob rau cov neeg laus uas muaj mob leukemia lymphocytic (CLL) lossis mob lymphocytic lymphoma me me (SLL) uas tau txais tsawg kawg ib qho kev kho mob systemic ua ntej, suav nrog Bruton's tyrosine kinase (BTK) inhibitor.
Pirtobrutinib yog ib qho tshuaj kinase inhibitor uas xaiv tau zoo heev uas siv cov txheej txheem tshiab uas tsis yog covalent los txuas ntxiv qhov txiaj ntsig ntawm kev tsom mus rau txoj kev BTK hauv cov neeg mob CLL/SLL uas tau kho nrog covalent BTK inhibitor (ibrutinib, acalabrutinib, lossis zanubrutinib). Pirtobrutinib tau txais kev pom zoo los ntawm US FDA thaum Lub Ib Hlis 2023 ua ib qho tshuaj BTK inhibitor uas tsis yog covalent (rov qab tau). Thaum Lub Kaum Hli 2024, pirtobrutinib tau pom zoo hauv Suav teb ua ib qho kev kho mob monotherapy rau kev kho mob rau cov neeg mob laus uas muaj mob rov qab los yog tsis kho tau mantle cell lymphoma (MCL) uas tau txais tsawg kawg yog ob qho kev kho mob systemic yav dhau los, suav nrog Bruton's tyrosine kinase (BTK) inhibitor.
Kev pom zoo rau qhov cim tshiab no yog raws li cov txiaj ntsig los ntawm kev tshawb fawb thoob ntiaj teb, ntau lub chaw, randomized, Theem 3 BRUIN CLL 321. BRUIN CLL 321 yog thawj qhov kev sim Theem 3 hauv ntiaj teb uas tau ua rau cov neeg mob uas muaj CLL/SLL uas tau kho nrog covalent BTK inhibitor (cBTKi) yav dhau los. Kev tshawb fawb tau sau npe rau tag nrho 238 tus neeg mob thiab soj ntsuam qhov ua tau zoo thiab kev nyab xeeb ntawm pirtobrutinib monotherapy piv rau tus kws tshawb fawb xaiv IdelaR (idelalisib ntxiv rau rituximab) lossis BR (bendamustine ntxiv rau rituximab). Cov txiaj ntsig tau qhia tias pirtobrutinib ntev dua qhov nruab nrab ntawm kev ciaj sia tsis muaj kev vam meej (PFS) piv rau tus kws tshawb fawb xaiv regimen (14.0 lub hlis vs 8.7 lub hlis; qhov piv txwv txaus ntshai [HR] = 0.54). Ntxiv rau, tus nqi tso tseg vim muaj kev phiv tshuaj uas cuam tshuam nrog kev kho mob qis dua nrog pirtobrutinib (5.2% vs 21.1%), txhawb nqa nws cov txiaj ntsig zoo thiab kev kam rau siab hauv cov neeg mob uas tau kho nrog covalent BTK inhibitor yav dhau los.
Tiv Tauj Peb Kom Pib Koj Txoj Kev Mus Los Ntawm Kev Cia Siab
Lub Tsev Kho Mob Thoob Ntiaj Teb ntawm Beijing South Region Oncology Hospital mob siab rau kev muab kev kho mob qog noj ntshav zoo tshaj plaws rau cov neeg mob thoob ntiaj teb. Yog tias koj lossis ib tug neeg hauv tsev neeg raug kuaj pom tias muaj qog noj ntshav thiab tsis tau teb zoo rau cov kev kho mob ib txwm muaj, peb pab neeg International Patient Services npaj txhij los muab cov ntaub ntawv qhia txog kev kho mob rau koj.
Thov hu rau peb los ntawm cov channel hauv qab no kom paub ntau ntxiv txog cov kev xaiv kho mob qog noj ntshav:
- Xov tooj: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Lub Tsev Kho Mob Thoob Ntiaj Teb ntawm Beijing South Region Oncology Hospital tos ntsoov yuav koom tes nrog koj hauv kev tawm tsam mob qog noj ntshav. Txawm koj nyob qhov twg hauv ntiaj teb no los xij, peb cog lus tias yuav muab kev txhawb nqa kev kho mob thiab kev saib xyuas zoo tshaj plaws rau koj.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Lub sijhawm tshaj tawm: Lub Peb Hlis-12-2026